Raltegravir N22-145S022 Clinical PREA

First Page		Document Content
Amides Organic chemistry Merck Oxadiazoles Raltegravir Antiretroviral drug Merck & Co. Integrase Clinical trial Chemistry Integrase inhibitors Organofluorides		Raltegravir N22-145S022 Clinical PREA Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 3,03 MB Share Document on Facebook

	Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation Kellie A. Juradoa, Hao Wanga, Alison Slaughterb, Lei Fengb, Jacques J. Kesslb, Yasuhiro Koha, Weifeng Wanga, Alliso DocID: 1uOOF - View Document
	June 17, 2009 Chemicals Targeting an HIV‐1 Nef/Host Cell Kinase Complex as Novel Anti‐ Retroviral Compounds Damilola A. Adepegba, Department of Natural Sciences, University of Maryland DocID: 1qLnJ - View Document
	Title Authors Affiliations DocID: 1qIsB - View Document
	GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a reasonable testing program, the product referenced in this certificate complies with applicable regulations DocID: 1aVDG - View Document
	Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav DocID: 1ai1w - View Document